Polyneuron Pharmaceuticals
Polyneuron Pharmaceuticals develops injectable glycopolymers designed to selectively eliminate pathological autoantibodies in patients with antibody-mediated autoimmune diseases. The company utilizes its Antibody-Catch technology platform to create decoy epitopes that sequester disease-causing antibodies while leaving the rest of the immune system intact. Its lead clinical candidate, PN-1007, targets anti-MAG neuropathy, a chronic disorder of the peripheral nervous system.
Healthtech
Biotechnology
Pharmaceuticals
Life Sciences
Funding summary
- Total raised
- €2.7M
- Funding rounds
- 1
Investors in Polyneuron Pharmaceuticals
Investors on record for Polyneuron Pharmaceuticals. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Polyneuron Pharmaceuticals?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors